With offices in New York City and Princeton, NJ, Noom has been named one of Inc.s Best Places to Work and Fortunes Best
doi: 10.3810/pgm.2013.05.2660
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function
Supports appetite regulation and metabolic balance GLP-1/GIP care for appetite regulation and metabolic balance Talk with our team and learn more before you begin GLP-1 microdosing uses a low weekly dose to help support appetite regulation and metabolic balance
Risk is highest during the initial titration phase and subsequent dose increases, particularly in vulnerable populations such as older adults or those with pre-existing conditions
Customizing Your Treatment Our board-certified providers may prescribe FDA-approved medications such as semaglutide, tirzepatide, phentermine, or a combination
